Synairgen plc Result of AGM (4198R)
29 Giugno 2020 - 4:18PM
UK Regulatory
TIDMSNG
RNS Number : 4198R
Synairgen plc
29 June 2020
RNS
Press release
Synairgen plc
('Synairgen' or the 'Company')
Result of AGM
Southampton, UK - 29 June 2020: Synairgen plc (LSE: SNG), the
respiratory drug discovery and development company, is pleased to
announce that all resolutions proposed at its Annual General
Meeting, held earlier today, were duly passed.
The full results of the proxy voting can be found on the
Company's website:
https://www.synairgen.com/wp-content/uploads/2020/06/2020-AGM-proxy-vote-summary.pdf
-Ends-
For further enquiries, please contact:
Synairgen plc
Richard Marsden, Chief Executive Officer
John Ward, Finance Director
Tel: + 44 (0) 23 8051 2800
finnCap
Geoff Nash, Kate Bannatyne, Charlie Beeson (Corporate
Finance)
Alice Lane, Manasa Patil (ECM)
Tel: + 44 (0) 20 7220 0500
Consilium Strategic Communications (Financial Media and
Investor
Relations)
Mary-Jane Elliott, Sue Stuart, Olivia Manser
synairgen@consilium-comms.com
Tel: +44 (0) 20 3709 5700
Notes for Editors
About Synairgen
Synairgen is a respiratory drug discovery and development
company founded by University of Southampton Professors Stephen
Holgate, Donna Davies and Ratko Djukanovic. The business, focused
primarily on lung viral defence in asthma and COPD, uses its
differentiating human biology BioBank platform and world-renowned
international academic KOL network to discover and develop novel
therapies for respiratory disease.
Synairgen is conducting a double blind, placebo-controlled
clinical trial in COVID-19 patients (SG016). The 220 patient trial
comprises 100 patients to be initiated in hospital and 120 patients
to be initiated in the home setting. A successful outcome will
inform onwards progression of SNG001 in COVID-19 patients. Results
from the hospital setting are expected in July 2020.
Synairgen is quoted on AIM (LSE: SNG). For more information
about Synairgen, please see www.synairgen.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
RAGBSGDLUBDDGGC
(END) Dow Jones Newswires
June 29, 2020 10:18 ET (14:18 GMT)
Grafico Azioni Synairgen (LSE:SNG)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Synairgen (LSE:SNG)
Storico
Da Apr 2023 a Apr 2024
